• Patient must have an indwelling radial or a femoral arterial catheter.
• Patient must be on norepinephrine, epinephrine, phenylephrine for hypotension
• Patient, or legal guardian, has given consent to be in the study.
• Patient must be at least 18 years old.
• Patient height and weight are available prior to study start and as required during the study period.
• Patients with contraindications for the placement of peripheral and/or central arterial cannulae.
• Patients with significant aortic valve regurgitation
• Patients being treated with an intraaortic balloon pump.
• Patients less than 40 kg in weight.
• Female patients with a known pregnancy. Pregnancy has known special cardiovascular physiology that may make it difficult to interpret the comparison data.
• Patient is currently participating in an investigational drug or another device study that has not completed the primary endpoint or that clinically interferes with the study endpoints.
Study investigator(s) and support staff will be trained by an Edwards Lifesciences representative or designee on the use of the device (DFU), the protocol, laptop set-up for data acquisition, and case report forms (CRFs). All training will be documented on a Training Log provided by Edwards Lifesciences, which all trainees must sign and date. In addition, a “Delegation of Authority Form” will be completed at each site designating which individuals are allowed to perform specific study related tasks.
The data collection system will be shipped and the set-up demonstrated during enrollment of the first patients. Additional shipment of any Edwards Lifesciences devices or system hardware will be provided by contacting the study representative. Patient Screening
• Enrollment
There is no randomization scheme in this study. Patients will be enrolled consecutively so as not to show any bias in subject selection. A total of 20 patients will be enrolled.
• Check that the patient parameters entered into the Vigileo™ are correct (Gender, Age, Height and Weight or BSA. If not, make the necessary changes, wait 10 minutes, and then continue with this procedure.
• Check that the FloTrac™ Sensor is at the level of the patient's heart. If it is not, position the FloTrac™ at the level of the patient's heart, re-zero the sensor, wait 10 minutes, and then start this procedure from step 2.
• Check that the FloTrac™, including its tubing to the patient, is free of air bubbles. If de-bubbling is required, de-bubble the line, re-zero the sensor, wait 10 minutes, and then continue this procedure at step 5.